Hansa Biopharma AB

09/12/2022 | Press release | Distributed by Public on 09/12/2022 07:37

The Scottish Medicines Consortium (SMC) recommends use of Hansa Biopharma’s Idefirix[®] (imlifidase) as desensitization treatment for highly sensitized kidney transplant patients